The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a TYK2/JAK1 Inhibitor (PF-06700841) in Healthy Subjects and Patients With Plaque Psoriasis-Reference-Cited by-同舟云学术

The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a TYK2/JAK1 Inhibitor (PF-06700841) in Healthy Subjects and Patients With Plaque Psoriasis

Published:2017-12-21 Issue:4 Volume:58 Page:434-447
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:The Journal of Clinical Pharmacology

Author:

Banfield Christopher¹,Scaramozza Matthew¹,Zhang Weidong¹,Kieras Elizabeth¹,Page Karen M.¹,Fensome Andrew¹,Vincent Michael¹,Dowty Martin E.¹,Goteti Kosalaram¹,Winkle Peter J.²,Peeva Elena¹

Affiliation:

1. Pfizer; Cambridge MA USA

2. Anaheim Clinical Trials; CA USA

Funder

Pfizer

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Reference33 articles.

1. Janus kinase inhibitors in autoimmune diseases;O'Shea;Ann Rheum Dis,2013

2. Direct binding to and tyrosine phosphorylation of the alpha subunit of the type I interferon receptor by p135tyk2 tyrosine kinase;Colamonici;Mol Cell Biol,1994

3. The human interferon alpha/beta receptor: characterization and molecular cloning;Novick;Cell,1994

4. Differential tyrosine phosphorylation of the IFNAR chain of the type I interferon receptor and of an associated surface protein in response to IFN-alpha and IFN-beta.;Abramovich;EMBO J,1994

5. IL-10 induces the tyrosine phosphorylation of tyk2 and Jak1 and the differential assembly of STAT1 alpha and STAT3 complexes in human T cells and monocytes;Finbloom;J Immunol,1995

Cited by 79 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery of selective TYK2 inhibitors: Design, synthesis, in vitro and in silico studies of promising hits with triazolopyrimidinone scaffold;Bioorganic Chemistry;2024-07

2. Therapeutic Potential of Targeting the JAK/STAT Pathway in Psoriasis: Focus on TYK2 Inhibition;Journal of Clinical Medicine;2024-05-24

3. The Metabolism and Disposition of Brepocitinib in Humans and Characterization of the Formation Mechanism of an Aminopyridine Metabolite;Drug Metabolism and Disposition;2024-05-07

4. Master protocols and other innovative trial designs in inflammation and immunology to expedite clinical drug development;Drug Discovery Today;2024-05

5. TYK2: an emerging therapeutic target in rheumatic disease;Nature Reviews Rheumatology;2024-03-11